Kronos Bio Inc. Completes Merger with Concentra Biosciences, Becoming a Wholly Owned Subsidiary
Kronos Bio Inc. has completed its merger with Concentra Biosciences, LLC, with Concentra's subsidiary acquiring approximately 72.90% of Kronos Bio's shares at $0.57 each. The merger was finalized on June 20, 2025, making Kronos Bio a wholly owned subsidiary of Concentra. The tender offer expired on June 18, 2025.
Kronos Bio Inc. announced the completion of its merger with Concentra Biosciences, LLC. As per the terms of the agreement, Concentra’s wholly owned subsidiary, Concentra Merger Sub IV, Inc., completed a tender offer to acquire all outstanding shares of Kronos Bio for $0.57 per share in cash, along with a non-transferable contractual contingent value right per share. The tender offer expired on June 18, 2025, and successfully resulted in the acquisition of approximately 72.90% of Kronos Bio’s outstanding shares. Following the satisfaction of all conditions, the merger was finalized on June 20, 2025, with Kronos Bio continuing as a wholly owned subsidiary of Concentra. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-055915), on June 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
